Therefore, similar to the oncogene Ras and the Ras-mediated MAPK pathway, ARF1 and ARF1-mediated ERK1/2 activation may represent novel molecular targets for prostate cancer therapeutics and diagnosis. This evidence concerns the gene ARF1 and prostate carcinoma.